Spondyloarthritis & psoriatic arthritis
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
Authors' conclusion
Patients with PsA starting a bDMARD in RCTs had highly active disease and a high patient-reported disease burden. In contrast, PsABio real-world patients starting a bDMARD had lower SJC/TJC, skin involvement, and PGA, but presented with similar patient-reported disease burden.
Study context
- Population
- Patients with PsA starting a bDMARD in phase III randomized controlled trials (RCTs) and in a real-world observational study10 RCTs
- Participants
- 5,654 vs 930
- Comparison
- Baseline characteristics of PsA patients in RCTs of biologic disease-modifying antirheumatic drugs (bDMARDs) vs a real-world study (PsABio)
- RCTsn = 5,654
- PsABion = 930reference
- Outcome
- Baseline patient characteristics (SJC/TJC, enthesitis, BSA, CRP, PGA, PROs), pooled means and proportions
- Follow-up
- Baseline
Methodological detailsunivariate random effects meta-analysis, phase III RCTs of bDMARDs 2015–2020 vs international observational study (PsABio)
- Univariate random effects meta-analysis
- Phase III RCTs of bDMARDs 2015–2020 vs international observational study (PsABio)
Pooled result
As reported in the abstract
Baseline characteristics
- SJC/TJC pooled means, RCTs vs PsABio
- 11.8/21.5 vs 5.7/11.9
- Enthesitis, RCTs vs PsABio
- 64.7% vs 48.2%
- BSA ≥ 3%, RCTs vs PsABio
- 62.2% vs 54%
- Physician global assessment (PGA), RCTs vs PsABio
- 59.7 vs 54.1
- C-reactive protein (CRP) significantly higher in PsABio, PsABio vs RCTs (mg/dL)
- 1.4 vs 1.1
Original publication
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis. J Rheumatol. Published 15 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →